FRM
DICE

Fox Run Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Fox Run Management’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,901
Closed -$309K – 992
2022
Q4 		$309K Buy
+9,901
New +$323K 0.12% 339

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fox Run Management's DICE Position: Q1 2023 in Review

Fox Run Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q1 2023, closing a stake of 9,901 shares — an estimated $309K sold.

Fox Run Management first reported a position in DICE in Q4 2022 and held it in 1 quarter. The position peaked at $309K in Q4 2022. 115 funds tracked by Wall St. Rank hold DICE as of Q1 2023.

  • Fox Run Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 9,901 DICE Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $309K.
  • Fox Run Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Fox Run Management's DICE Therapeutics, Inc. Common Stock position peaked at $309K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.